참고문헌
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30 https://doi.org/10.3322/caac.21166
- Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases. Br J Haematol 2004;124:151-159 https://doi.org/10.1046/j.1365-2141.2003.04749.x
- Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 2011;117:2530-2540 https://doi.org/10.1002/cncr.25765
- Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008;105:13520-13525 https://doi.org/10.1073/pnas.0804295105
- Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004;165:159-166 https://doi.org/10.1016/S0002-9440(10)63284-1
- Basso K, Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol 2010;105:193-210
- Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-3537 https://doi.org/10.1182/blood-2009-05-220095
- Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874 https://doi.org/10.1084/jem.194.12.1861
- Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676-1679 https://doi.org/10.1126/science.1153629
- Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010;116:3268-3277 https://doi.org/10.1182/blood-2010-05-282780
- Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-862 https://doi.org/10.1084/jem.20031074
- Cazals-Hatem D, Lepage E, Brice P, Ferrant A, d'Agay MF, Baumelou E, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol 1996;20:877-888 https://doi.org/10.1097/00000478-199607000-00012
- Dunleavy K, Grant C, Eberle FC, Pittaluga S, Jaffe ES, Wilson WH. Gray zone lymphoma: better treated like Hodgkin lymphoma or mediastinal large B-cell lymphoma? Curr Hematol Malig Rep 2012;7:241-247 https://doi.org/10.1007/s11899-012-0130-5
- Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, et al. Double-hit B-cell lymphomas. Blood 2011;117:2319-2331 https://doi.org/10.1182/blood-2010-09-297879
- Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006 https://doi.org/10.1056/NEJM199304083281404
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242 https://doi.org/10.1056/NEJMoa011795
- Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-2045 https://doi.org/10.1182/blood-2010-03-276246
- Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 2016;13:25-40 https://doi.org/10.1038/nrclinonc.2015.187
- Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 2016;127:1410-1416 https://doi.org/10.1182/blood-2015-06-651380
- Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapyrefractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540-549 https://doi.org/10.1200/JCO.2014.56.2025
- Sanford M. Blinatumomab: first global approval. Drugs 2015;75:321-327 https://doi.org/10.1007/s40265-015-0356-3
- Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57-66 https://doi.org/10.1016/S1470-2045(14)71170-2
- Buie LW, Pecoraro JJ, Horvat TZ, Daley RJ. Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia. Ann Pharmacother 2015;49:1057-1067 https://doi.org/10.1177/1060028015588555
- Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol 2016;34:1104-1111 https://doi.org/10.1200/JCO.2014.59.1586
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264 https://doi.org/10.1038/nrc3239
- Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526 https://doi.org/10.1056/NEJMoa1104621
- Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-319 https://doi.org/10.1056/NEJMoa1411087
- Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013;31:4199-4206 https://doi.org/10.1200/JCO.2012.48.3685
- Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011;2011:498-505 https://doi.org/10.1182/asheducation-2011.1.498
- Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer 2014;3:66-70 https://doi.org/10.4103/2278-330X.126531
- Ahuja AT, Ying M, Ho SY, Antonio G, Lee YP, King AD, et al. Ultrasound of malignant cervical lymph nodes. Cancer Imaging 2008;8:48-56 https://doi.org/10.1102/1470-7330.2008.0006
- Ahuja AT, Ying M, Yuen HY, Metreweli C. 'Pseudocystic' appearance of non-Hodgkin's lymphomatous nodes: an infrequent finding with high-resolution transducers. Clin Radiol 2001;56:111-115 https://doi.org/10.1053/crad.2000.0642
- McInnes MD, Kielar AZ, Macdonald DB. Percutaneous imageguided biopsy of the spleen: systematic review and metaanalysis of the complication rate and diagnostic accuracy. Radiology 2011;260:699-708 https://doi.org/10.1148/radiol.11110333
- Burke C, Thomas R, Inglis C, Baldwin A, Ramesar K, Grace R, et al. Ultrasound-guided core biopsy in the diagnosis of lymphoma of the head and neck. A 9 year experience. Br J Radiol 2011;84:727-732 https://doi.org/10.1259/bjr/60580076
- Larcos G, Farlow DC, Antico VF, Gruenewald SM, Boyages J. The role of high dose 67-gallium scintigraphy in staging untreated patients with lymphoma. Aust N Z J Med 1994;24:5-8 https://doi.org/10.1111/j.1445-5994.1994.tb04417.x
- Israel O, Front D, Epelbaum R, Ben-Haim S, Jerushalmi J, Kleinhaus U, et al. Residual mass and negative gallium scintigraphy in treated lymphoma. J Nucl Med 1990;31:365-368
- Front D, Bar-Shalom R, Epelbaum R, Haim N, Ben-Arush MW, Ben-Shahar M, et al. Early detection of lymphoma recurrence with gallium-67 scintigraphy. J Nucl Med 1993;34:2101-2104
- Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-3068 https://doi.org/10.1200/JCO.2013.54.8800
- NCCN. Non-Hodgkin's Lymphomas. Washington, DC: NCCN, 2016.
- Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-842 https://doi.org/10.1182/blood-2013-09-524108
- Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol 2015;4:5
- Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-1854 https://doi.org/10.1200/JCO.2010.32.5225
- Vriens D, Visser EP, de Geus-Oei LF, Oyen WJ. Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging 2010;37:1408-1425 https://doi.org/10.1007/s00259-009-1306-7
- Kostakoglu L, Cheson BD. State-of-the-art research on "Lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response". Front Oncol 2013;3:212
- Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 2013;54:1244-1250 https://doi.org/10.2967/jnumed.112.114710
- Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Klerk JM, et al. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol 2014;89:726-731 https://doi.org/10.1002/ajh.23730
- Cerci JJ, Gyorke T, Fanti S, Paez D, Meneghetti JC, Redondo F, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med 2014;55:1591-1597 https://doi.org/10.2967/jnumed.113.134486
- Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-578 https://doi.org/10.1200/JCO.2006.08.2305
- Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PETscan in lymphoma. Leuk Lymphoma 2009;50:1257-1260 https://doi.org/10.1080/10428190903040048
-
Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Vera P, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and
${\Delta}SUVmax$ . Eur J Nucl Med Mol Imaging 2013;40:1312-1320 https://doi.org/10.1007/s00259-013-2435-6 - Carr R, Fanti S, Paez D, Cerci J, Gyorke T, Redondo F, et al. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med 2014;55:1936-1944 https://doi.org/10.2967/jnumed.114.145326
- Duhrsen U, Huttmann A, Jockel KH, Muller S. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial. Leuk Lymphoma 2009;50:1757-1760 https://doi.org/10.3109/10428190903308031
- van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the sideeffects of rituximab treatment. Br J Haematol 2001;115:807-811 https://doi.org/10.1046/j.1365-2141.2001.03166.x
- Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 2012;51:653-662 https://doi.org/10.1093/rheumatology/ker290
- Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Br J Haematol 2015;170:185-191 https://doi.org/10.1111/bjh.13420
- Coughlan M, Elstrom R. The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy. Cancer Imaging 2014;14:34 https://doi.org/10.1186/s40644-014-0034-9
- Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B, et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002;30:103-111 https://doi.org/10.1038/sj.bmt.1703607
- Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood 2015;125:2579-2581 https://doi.org/10.1182/blood-2014-10-606939
- Brastianos PK, Batchelor TT. Primary central nervous system lymphoma: overview of current treatment strategies. Hematol Oncol Clin North Am 2012;26:897-916 https://doi.org/10.1016/j.hoc.2012.05.003
- Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 2013;9:317-327 https://doi.org/10.1038/nrneurol.2013.83
- Mohile NA, Abrey LE. Primary central nervous system lymphoma. Neurol Clin 2007;25:1193-1207, xi https://doi.org/10.1016/j.ncl.2007.07.001
- Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, et al. Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood 2010;115:5005-5011 https://doi.org/10.1182/blood-2009-12-258210
- Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 1997;54:854-859 https://doi.org/10.1001/archneur.1997.00550190044013
- Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol 2008;10:223-228 https://doi.org/10.1215/15228517-2007-061
- Mayerhoefer ME, Karanikas G, Kletter K, Prosch H, Kiesewetter B, Skrabs C, et al. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Clin Cancer Res 2014;20:2984-2993 https://doi.org/10.1158/1078-0432.CCR-13-3355
- Littooij AS, Kwee TC, Barber I, Granata C, Vermoolen MA, Enriquez G, et al. Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard. Eur Radiol 2014;24:1153-1165 https://doi.org/10.1007/s00330-014-3114-0
- Heacock L, Weissbrot J, Raad R, Campbell N, Friedman KP, Ponzo F, et al. PET/MRI for the evaluation of patients with lymphoma: initial observations. AJR Am J Roentgenol 2015;204:842-848 https://doi.org/10.2214/AJR.14.13181
- Herrmann K, Queiroz M, Huellner MW, de Galiza Barbosa F, Buck A, Schaefer N, et al. Diagnostic performance of FDGPET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. BMC Cancer 2015;15:1002 https://doi.org/10.1186/s12885-015-2009-z
- Riedel DJ, Rositch AF, Redfield RR, Blattner WA. HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population. Leuk Lymphoma 2016;57:306-312 https://doi.org/10.3109/10428194.2015.1055483
- Agarwal PA, Menon S, Smruti BK, Singhal BS. Primary central nervous system lymphoma: a profile of 26 cases from Western India. Neurol India 2009;57:756-763 https://doi.org/10.4103/0028-3886.59472
- Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 2011;101:257-265 https://doi.org/10.1007/s11060-010-0252-3
- Johnson BA, Fram EK, Johnson PC, Jacobowitz R. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol 1997;18:563-572
- Hare SS, Souza CA, Bain G, Seely JM, Frcpc, Gomes MM, et al. The radiological spectrum of pulmonary lymphoproliferative disease. Br J Radiol 2012;85:848-864 https://doi.org/10.1259/bjr/16420165
- Anis M, Irshad A. Imaging of abdominal lymphoma. Radiol Clin North Am 2008;46:265-285, viii-ix https://doi.org/10.1016/j.rcl.2008.04.001
- Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-1336 https://doi.org/10.1038/3337
-
Leng K. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. 3'-Deoxy-3'-[
$^{18}F$ ]fluorothymidine. http://www.ncbi.nlm.nih.gov/books/NBK23373/. Accessed January 15, 2015 - Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263:8350-8358
- Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG. J Nucl Med 2008;49:186-194 https://doi.org/10.2967/jnumed.107.044966
- Zhao S, Kuge Y, Kohanawa M, Takahashi T, Zhao Y, Yi M, et al. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT. J Nucl Med 2008;49:135-141
- Troost EG, Vogel WV, Merkx MA, Slootweg PJ, Marres HA, Peeters WJ, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007;48:726-735 https://doi.org/10.2967/jnumed.106.037473
- Tadmor T, Shvidel L, Bairey O, Goldschmidt N, Ruchlemer R, Fineman R, et al. Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group. Am J Hematol 2014;89:E218-E222 https://doi.org/10.1002/ajh.23826
- Giardino AA, O'Regan K, Jagannathan JP, Elco C, Ramaiya N, Lacasce A. Richter's transformation of chronic lymphocytic leukemia. J Clin Oncol 2011;29:e274-e276 https://doi.org/10.1200/JCO.2010.32.6579
- Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006;47:1267-1273
- Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 2014;123:2783-2790 https://doi.org/10.1182/blood-2013-11-536169
- Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523-531
- Zuckerman D, Seliem R, Hochberg E. Intravascular lymphoma: the oncologist's "great imitator". Oncologist 2006;11:496-502 https://doi.org/10.1634/theoncologist.11-5-496
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th ed. Lyon: IARC, 2008
- Shimada K, Kinoshita T, Naoe T, Nakamura S. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 2009;10:895-902 https://doi.org/10.1016/S1470-2045(09)70140-8
- Yamamoto A, Kikuchi Y, Homma K, O'uchi T, Furui S. Characteristics of intravascular large B-cell lymphoma on cerebral MR imaging. AJNR Am J Neuroradiol 2012;33:292-296 https://doi.org/10.3174/ajnr.A2770
- Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol 2015;33:1467-1474 https://doi.org/10.1200/JCO.2014.58.5729
- Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol 2014;32:3506-3512 https://doi.org/10.1200/JCO.2014.55.7561
피인용 문헌
- Multimodality imaging-based evaluation of Rosai–Dorfman disease in the head and neck : A retrospective observational study vol.96, pp.51, 2017, https://doi.org/10.1097/md.0000000000009372
- Stensen Duct Relapse of Diffuse Large B-Cell Lymphoma: An Unusual Pattern Detected With 18F-FDG PET/CT vol.42, pp.7, 2017, https://doi.org/10.1097/rlu.0000000000001688
- Structured reporting adds clinical value in primary CT staging of diffuse large B-cell lymphoma vol.28, pp.9, 2018, https://doi.org/10.1007/s00330-018-5340-3
- Multiple primary tumors: Colorectal carcinoma and non-Hodgkin’s lymphoma vol.48, pp.None, 2017, https://doi.org/10.1016/j.ijscr.2018.05.010
- A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology vol.20, pp.12, 2019, https://doi.org/10.3348/kjr.2019.0928
- Biomimetic Magnetic Nanostructures: A Theranostic Platform Targeting Lipid Metabolism and Immune Response in Lymphoma vol.13, pp.9, 2017, https://doi.org/10.1021/acsnano.9b03727
- Characteristics of Recent Articles Published in the Korean Journal of Radiology Based on the Citation Frequency vol.21, pp.12, 2020, https://doi.org/10.3348/kjr.2020.1322
- Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art vol.38, pp.1, 2020, https://doi.org/10.1002/hon.2676
- Spectrum of imaging findings in AIDS-related diffuse large B cell lymphoma vol.11, pp.1, 2017, https://doi.org/10.1186/s13244-020-00871-w
- Whole-Body Magnetic Resonance Imaging: Current Role in Patients with Lymphoma vol.11, pp.6, 2017, https://doi.org/10.3390/diagnostics11061007